Martin Daniel C. 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Dec 14, 2023
Insider Transaction Report
Form 4
Martin Daniel C.
Chief Commercial Officer
Transactions
- Award
Common Stock
2023-12-12+5,576→ 51,011 total - Sale
Common Stock
2023-12-13$15.37/sh−1,727$26,539→ 49,284 total
Footnotes (2)
- [F1]On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 5,576 RSUs.
- [F2]This sale was to cover tax liabilities in the vesting of RSUs.